Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





Income Statement
Balance Sheet
Cash Flow Statement

Common Size IS
Op Efficiency
Credit Analysis

Astria Therapeutics, Inc. (ATXS)

Income Statement

Standardized | As Reported Annual | Quarterly | TTM
  Older >>
In millions, except per share itemsDec-31-22Dec-31-21Dec-31-20Dec-31-19Dec-31-18Dec-31-17Dec-31-16Dec-31-15
   10-K10-K10-K10-K/A10-K10-K10-K10-K
Operating expenses:          
Research and development  34.315.625.618.317.018.725.523.0
General and administrative  19.214.811.88.89.38.910.18.6
    Total operating expenses  53.5195.037.427.126.427.635.631.7
    Loss from operations  -53.5-195.0-37.4-27.1-26.4-27.1-35.6-31.7
   
Other income (expense):          
Interest and investment income  1.70.10.20.80.40.20.2 
Other expense, net  -0.1-0.1-0.1-0.10.20.00.10.0
    Total other income, net  1.70.10.10.80.5-0.3-0.5-1.0
    Net loss  -51.8-194.9-37.3-26.3-25.9-27.4-36.1-32.6
   
Net loss per share attributable to common shareholders - basic  ($3.55)($24.58)($12.20)($2.35)($5.12)($12.62)($2.22)($4.06)
Net loss per share attributable to common shareholders - diluted  ($3.55)($24.58)($12.20)($2.35)($5.12)($12.62)($2.22)($4.06)
   
Weighted-average common shares outstanding used in net loss per share - basic  14.68.93.111.25.12.216.28.0
Weighted-average common shares outstanding used in net loss per share - diluted  14.68.93.1     

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy